Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscles cells

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 3, 2010, Pages 362-367

  Sun, Xiu Zhen ^a   Li, Zong Fang ^a   Liu, Yun ^a   Fang, Ping ^a   Li, Man Xiang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Endothelin 1; Matrix metalloproteinase 2; Phosphodiesterase 5; Rho associated kinase; RhoA; Vascular smooth muscle cells

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; ENDOTHELIN 1; GELATINASE A; PHOSPHODIESTERASE V; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SILDENAFIL;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; LUNG BLOOD VESSEL; NONHUMAN; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER;

ANIMALS; CELLS, CULTURED; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; MATRIX METALLOPROTEINASE 2; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHODIESTERASE 5 INHIBITORS; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77649106196     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05304.x     Document Type: Article

References (47)

1. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 2006 98 : 322 334.
2. McNamara PJ, Murthy P, Kantores C et al. Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008 294 : L205 13.
3. Abe K, Shimokawa H, Morikawa K et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 2004 94 : 385 393.
4. Wang Z, Jin N, Ganguli S, Swartz DR, Li L, Rhoades RA. Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. Am. J. Respir. Cell Mol. Biol. 2001 25 : 628 635.
5. Broughton BR, Walker BR, Resta TC. Chronic hypoxia induces Rho kinase-dependent myogenic tone in small pulmonary arteries. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008 294 : L797 806.
6. Li M, Liu Y, Dutt P, Fanburg BL, Toksoz D. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007 293 : L463 71.
7. Ho PY, Zhong WB, Ho YS, Lee WS. Terbinafine inhibits endothelial cell migration through suppression of the Rho-mediated pathway. Mol. Cancer Ther. 2006 5 : 3130 3138.
8. Turner NA, O'Regan DJ, Ball SG, Porter KE. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J. 2005 19 : 804 806.
9. Fromigue O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J. Biol. Chem. 2008 283 : 30549 30556.
10. Kohno Y, Tanimoto A, Cirathaworn C, Shimajiri S, Tawara A, Sasaguri Y. GM-CSF activates RhoA, integrin and MMP expression in human monocytic cells. Pathol. Int. 2004 54 : 693 702.
11. Li M, Li Z, Sun X. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells. Eur. J. Pharmacol. 2008 591 : 219 223.
12. Somerville RP, Oblander SA, Apte SS. Matrix metalloproteinases: Old dogs with new tricks. Genome Biol. 2003 4 : 216.1 11.
13. Lepetit H, Eddahibi S, Fadel E et al. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2005 25 : 834 842.
14. Frisdal E, Gest V, Vieillard-Baron A et al. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur. Respir. J. 2001 18 : 838 845.
15. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion. Opportunities and obstacles for survival signaling. Br. J. Pharmacol. 2007 152 : 855 869.
16. Kirsch M, Kemp-Harper B, Weissmann N, Grimminger F, Schmidt HH. Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling. FASEB J. 2008 22 : 30 40.
17. Wharton J, Strange JW, Moller GM et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. 2005 172 : 105 113.
18. Tantini B, Manes A, Fiumana E et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res. Cardiol. 2005 100 : 131 138.
19. Hemnes AR, Champion HC. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Expert Rev. Cardiovasc. Ther. 2006 4 : 293 300.
20. Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br. J. Pharmacol. 2002 137 : 1187 1194.
21. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil. From angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 2006 5 : 689 702.
22. Herrera EA, Ebensperger G, Krause BJ et al. Sildenafil reverses hypoxic pulmonary hypertension in highland and lowland newborn sheep. Pediatr. Res. 2008 63 : 169 175.
23. Larrue B, Jaillard S, Lorthioir M et al. Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005 288 : L1193 200.
24. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005 353 : 2148 2157. (Pubitemid 41653106)
25. Guilluy C, Sauzeau V, Rolli-Derkinderen M et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br. J. Pharmacol. 2005 146 : 1010 1018.
26. Golovina VA, Blaustein MP. Preparation of primary cultured mesenteric artery smooth muscle cells for fluorescent imaging and physiological studies. Nat. Protoc. 2006 1 : 2681 2687.
27. Pullamsetti S, Krick S, Yilmaz H et al. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir. Res. 2005 6 : 128.
28. Kuzuya M, Kanda S, Sasaki T et al. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 2003 108 : 1375 1381.
29. Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J. Clin. Invest. 2000 105 : 21 34.
30. Eddahibi S, Adnot S. Endothelins and pulmonary hypertension, what directions for the near future? Eur. Respir. J. 2001 18 : 1 4.
31. Ambalavanan N, Bulger A, Murphy-Ullrich J, Oparil S, Chen YF. Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling. Pediatr. Res. 2005 57 : 631 636.
32. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur. Respir. J. 2008 31 : 407 415.
33. A receptor antagonist LU-135252 selectively attenuates hypoxic pulmonary vasoconstriction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008 294 : R601 5.
34. Wedgwood S, Dettman RW, Black SM. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001 281 : L1058 67.
35. Davie N, Haleen SJ, Upton PD et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med. 2002 165 : 398 405. (Pubitemid 34118516)
36. Rosano L, Spinella F, Di Castro V et al. Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am. J. Pathol. 2003 163 : 753 762.
37. Ergul A, Portik-Dobos V, Giulumian AD, Molero MM, Fuchs LC. Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am. J. Physiol. Heart Circ. Physiol. 2003 285 : H2225 32.
38. Harris AK, Hutchinson JR, Sachidanandam K et al. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: Role of endothelin-1. Diabetes 2005 54 : 2638 2644.
39. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 2008 78 : 356 365.
40. Kuo L, Chang HC, Leu TH, Maa MC, Hung WC. Src oncogene activates MMP-2 expression via the ERK/Sp1 pathway. J. Cell. Physiol. 2006 207 : 729 734.
41. Liu Y, Suzuki YJ, Day RM, Fanburg BL. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ. Res. 2004 95 : 579 586.
42. Zhu S, Korzh V, Gong Z, Low BC. RhoA prevents apoptosis during zebrafish embryogenesis through activation of Mek/Erk pathway. Oncogene 2008 27 : 1580 1589.
43. Basile JR, Gavard J, Gutkind JS. Plexin-B1 utilizes RhoA and Rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility. J. Biol. Chem. 2007 282 : 34888 34895.
44. Akhmetshina A, Dees C, Pileckyte M et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum. 2008 58 : 2553 2564.
45. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: Expanding roles in cardiovascular regulation. Circ. Res. 2007 101 : 1084 1095.
46. Sawada N, Itoh H, Yamashita J et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem. Biophys. Res. Commun. 2001 280 : 798 805.
47. Ellerbroek SM, Wennerberg K, Burridge K. Serine phosphorylation negatively regulates RhoA in vivo. J. Biol. Chem. 2003 278 : 19023 19031.